Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2014

Angell Trevor E, Lechner Melissa G, Jang Julie K, LoPresti Jonathan S, Epstein Alan L

Abstract excerpt

PURPOSE: To evaluate MHC class I expression on papillary thyroid cancer (PTC) and analyze changes in MHC expression and associated immune activation with current and experimental treatments for thyroid cancer using in vitro PTC cell lines. EXPERIMENTAL DESIGN: MHC class I expression and assessment of tumor-infiltrating leukocyte populations were evaluated by immunohistochemistry. PTC cell lines were analyzed for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Papillary

Share to Drug Synergism

Share to Interferons

Share to Lymphocytes, Tumor-Infiltrating

Share to Thyroid Cancer, Papillary

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 25294906
DOI: 10.1158/1078-0432.CCR-14-0879
PMCID: PMC4252612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.PMID 25294906Read ↗

Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies.Semantic proximity Read ↗

Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapiesSemantic proximity Read ↗

The Prognostic Value and Potential Immune Mechanisms of lncRNAs Related to Immunogenic Cell Death in Papillary Thyroid CarcinomaSemantic proximity Read ↗

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Semantic proximity Read ↗

Comprehensive Immune Profiling of Medullary Thyroid Cancer.Semantic proximity Read ↗

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.Semantic proximity Read ↗

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid CancersSemantic proximity Read ↗

Gene expression and the biological phenotype of papillary thyroid carcinomas.Semantic proximity Read ↗

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.Semantic proximity Read ↗

Phenotypic and functional characterization of lymphocytes in autoimmune thyroiditis and in papillary carcinoma.Semantic proximity Read ↗

BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer.Semantic proximity Read ↗

Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.